Morphologic Changes in Patient with Drusen and Drusenoid Pigment Epithelial Detachment after Intravitreal Ranibizumab for Choroidal Neovascular Membrane : A Case Report



Sukjin Kim, Jeongjae Oh, Kiseok Kim*
Department of Ophthalmology, Saevit Eye Hospital, Goyangsi, Korea


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 642
Abstract HTML Views: 407
PDF Downloads: 144
ePub Downloads: 100
Total Views/Downloads: 1293
Unique Statistics:

Full-Text HTML Views: 424
Abstract HTML Views: 250
PDF Downloads: 97
ePub Downloads: 75
Total Views/Downloads: 846



© Kim et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Department of Ophthalmology, Saevit Eye Hospital #1334-3 Baekseok-dong, Ilsan dong-gu, Goyang-si, Gyeonggi-do, 410-817, Korea; Tel: 82-31-900-7700; Fax: 82-31-900-7777; E-mail: kiseok70@gmail.com


Abstract

The authors present a case of morphologic changes of drusen and drusenoid pigment epithelial detachment (DPED) after treating choroidal neovascularization (CNV) using ranibizumab in age-related macular degeneration (AMD). A 71-year-old woman has noticed mild visual acuity deterioration in the right eye for several months. She was presented with some drusen and DPED associated with CNV. This patient was given intravitreal injection of 0.5 mg of ranibizumab five times at monthly intervals for treating CNV. DPED in the temporal and drusen in the superior to macula were diminished, which continued up to 2 months. Intravitreal ranibizumab injection may have influenced with diminishment of drusen and DPED. After 2 months, CNV was recurred.

Keywords: Age-related macular degeneration, anti-VEGF (vascular endothelial growth factor), drusen, drusenoid pigment epithelial detachment, ranibizumab.